Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
J. Clin. Invest. Gabriele Bergers, et al. 111:1287
doi:10.1172/JCI17929 [Go to this article.]

Problems with a PDF?